In a recent ongoing clinical trial (NCT03524677), the relationship between the four major genes—KRAS, CDKN2A, SMAD4, TP53—involved in PDA progression and preoperative staging was investigated in order to better stratify patients for setting an optimal therapeutic strategy. This evidence concerns the gene KRAS and Patent ductus arteriosus.